Baytril 100 (enrofloxacin) Injectable, manufactured by Bayer HealthCare LLC, Animal Health division, recently received Food and Drug Administration (FDA) approval for treatment and control of swine respiratory disease (SRD) associated with bacterial pathogens Mycoplasma hyopneumoniae (M. Hyo) and Bordetella bronchiseptica (B. bronchiseptica).
"M. hyo causes mycoplasmal pneumonia of swine (MPS), or enzootic pneumonia, throughout the world and can become problematic if left untreated," said Dr. Andy Holtcamp, Bayer senior veterinarian, technical services. "These recent FDA approvals for Baytril 100 to treat and control SRD associated with M. hyo and B. bronchiseptica provide swine producers and veterinarians a powerful tool to treat and control six major swine pathogens."
The endemic, contagious respiratory diseases caused by M. hyo and B. bronchiseptica are spread by nose-to-nose contact, contaminated water or feed, as well as transmission from sows to piglets. Symptoms can include dry coughing, impaired growth rate and poor feed conversion. Secondary bacterial or viral infections commonly follow, which can result in more severe SRD.
"As a company, Bayer HealthCare Animal Health division is committed to providing quality solutions to the problems swine producers and swine veterinarians experience on an on-going basis," said Cary Christensen, DVM, director, Food Animal Business Unit, Bayer. "These latest FDA approvals fortify the strength we continue to observe with Baytril 100 for treatment and control of SRD in swine herds."
Baytril 100 is an effective treatment tool in pigs which are eight to 12 weeks along in the finishing stage to help knock down the "10-Week Wall" of respiratory disease. In addition, producers may use Baytril 100 as a health management tool to control SRD in the nursery and the farrowing barn.
Baytril 100 is the only approved fluoroquinolone class of products labeled for use in swine. It is bactericidal, which describes classes of drugs that reduce bacterial populations. Many other antibiotics are bacteriostatic, which do not kill bacteria but inhibit bacterial growth. Due to the mode of action of Baytril 100, it kills six major swine respiratory disease-causing bacteria in both the resting and growth phases of bacteria development by essentially killing the "heart" of the bacteria.
Baytril 100 is approved for treating and controlling SRD associated with the following pathogens: Mycoplasma hyopneumoniae (M. hyo), Bordetella bronchiseptica (B. bronchiseptica), Actinobacillus pleuropneumoniae (APP), Pasteurella multocida, Haemophilus parasuis and Streptococcus suis.